Clinical outcomes and thrombus resolution in patients with solid left atrial appendage thrombi: results of a single-center real-world registry

[1]  G. Lip,et al.  Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial , 2020, Clinical Research in Cardiology.

[2]  G. Nickenig,et al.  'What you see is what you'll get': giant extra-appendage left atrial thrombus after left atrial appendage occlusion for persisting left atrial appendage thrombus. , 2019, European heart journal cardiovascular Imaging.

[3]  S. Herget-Rosenthal,et al.  Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case–control studies , 2019, Clinical Research in Cardiology.

[4]  I. Sohn,et al.  Creatinine- and cystatin C-based estimated glomerular filtration rate slopes for the prediction of kidney outcome: a comparative retrospective study , 2019, BMC Nephrology.

[5]  Yan He,et al.  Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients , 2019, Journal of Thrombosis and Thrombolysis.

[6]  P. Mitro,et al.  Left atrial appendage strain rate is associated with documented thromboembolism in nonvalvular atrial fibrillation , 2019, Wiener klinische Wochenschrift.

[7]  S. Hohnloser,et al.  Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database , 2019, Clinical Research in Cardiology.

[8]  R. Siegel,et al.  Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation. , 2019, The American journal of cardiology.

[9]  J. Hoehns,et al.  A prospective, multi-center cohort study: investigating the ability of warfarin-treated patients to predict their INR , 2018, Clinical Research in Cardiology.

[10]  Á. Avezum,et al.  Efficacy and safety of dabigatran versus warfarin from the RE-LY trial , 2018, Open Heart.

[11]  Daniel Barbosa,et al.  MITT: Medical Image Tracking Toolbox , 2018, IEEE Transactions on Medical Imaging.

[12]  C. Gerloff,et al.  Expert opinion paper on atrial fibrillation detection after ischemic stroke , 2018, Clinical Research in Cardiology.

[13]  S. Schoenberg,et al.  Impact of left atrial appendage morphology on thrombus formation after successful left atrial appendage occlusion: Assessment with cardiac-computed-tomography , 2018, Scientific Reports.

[14]  Josef Kautzner,et al.  Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2018, European heart journal.

[15]  G. Nickenig,et al.  Thrombus Formation After Left Atrial Appendage Occlusion With the Amplatzer Amulet Device. , 2017, JACC. Clinical electrophysiology.

[16]  H. Thiele,et al.  Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists , 2016, European Journal of Medical Research.

[17]  Yuyang Chen,et al.  Effect of Metabolic Syndrome on Risk Stratification for Left Atrial or Left Atrial Appendage Thrombus Formation in Patients with Nonvalvular Atrial Fibrillation , 2016, Chinese medical journal.

[18]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  G. Lip,et al.  Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). , 2016, American heart journal.

[20]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[21]  Jan Balzer,et al.  Left atrial appendage morphology is closely associated with specific echocardiographic flow pattern in patients with atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[22]  G. Breithardt,et al.  Rationale and design of the RE-LATED AF—AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus—Effects of Dabigatran in patients with Atrial Fibrillation , 2015, Clinical Research in Cardiology.

[23]  Y. Ugawa,et al.  Risk factors for left atrial thrombus from transesophageal echocardiography findings in ischemic stroke patients. , 2014, Fukushima journal of medical science.

[24]  G. Nickenig,et al.  Left atrial appendage closure in a patient with atrial fibrillation after mechanical mitral valve replacement and cardio-embolic stroke despite effective oral anticoagulant therapy: a case report , 2014, Clinical Research in Cardiology.

[25]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[26]  G. Lip,et al.  Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature , 2012, Circulation.

[27]  M. Kawasaki,et al.  Left atrial appendage emptying fraction assessed by a feature-tracking echocardiographic method is a determinant of thrombus in patients with nonvalvular atrial fibrillation. , 2012, Journal of cardiology.

[28]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[29]  Warren J Manning,et al.  ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, , 2011, Journal of the American College of Cardiology.

[30]  D. Voora,et al.  Prevalence and Clinical Characteristics Associated With Left Atrial Appendage Thrombus in Fully Anticoagulated Patients Undergoing Catheter‐Directed Atrial Fibrillation Ablation , 2010, Journal of cardiovascular electrophysiology.

[31]  David D Spragg,et al.  Incidence and Predictors of Periprocedural Cerebrovascular Accident in Patients Undergoing Catheter Ablation of Atrial Fibrillation , 2009, Journal of cardiovascular electrophysiology.

[32]  Timothy Watson,et al.  Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited , 2009, The Lancet.

[33]  J. Gardin,et al.  American Society of Echocardiography recommendations for use of echocardiography in clinical trials. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[34]  C. Asher,et al.  The role of echocardiography in atrial fibrillation and cardioversion , 2003, Heart.

[35]  J. Thomas,et al.  Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. , 2000, American heart journal.

[36]  A. Camm,et al.  Left atrial appendage: structure, function, and role in thromboembolism , 1999, Heart.

[37]  S. Beppu,et al.  Smoke-like echo in the left atrial cavity in mitral valve disease: its features and significance. , 1985, Journal of the American College of Cardiology.